Spa Therapy in Anxiety Disorder in a 8 Week Comparative and Randomized Multicentre Study on 237 Patients

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
O. Dubois
Keyword(s):  
Anxiety Disorder ◽  
Multicentre Study ◽  
Rating Scale ◽  
Therapy Group ◽  
Spa Therapy ◽  
Generalized Anxiety ◽  
Generalized Anxiety Disorders ◽  
Spa Treatment ◽  
Dsm Iv ◽  
Hamilton Rating Scale

We compared spa therapy-like balneotherapy treatment with Paroxetine by means of a multicentre, comparative, randomized 8-week study. At least 200 patients fitting the diagnosed criteria of generalized anxiety disorder (DSM IV) were to be recruited. They were carried out by an independent, fully-trained and specialized assessor.The total score on the HAM-A scale (Hamilton Rating Scale for Anxiety) was the main measure for efficiency.There were 237 patients altogether attending in ambulatory who were admitted into the 4 French centres and joined the protocol. 117 were divided up by drawing lots into the Spa Therapy group and 120 into the Paroxetine group.All 207 patients were able to be assessed at W8. The HAM-A scores at W8 showed significant improvement in the Spa Therapy group compared to the Paroxetine group (t = 3.04 p≤ 0.0001). Remission and the rate of improvement (superior or equal to 50%) were markedly higher in the Spa Therapy group.Other analyses stemming from this assessment enrich the results, with complemetary information on the importance of a spa treatment course prescribed in a psychiatric aim.In conclusion, the Spa Therapy-based Balneotherapy treatment is one that has shown specific efficiency in generalized anxiety disorders. Its profile of being well-tolerated and well-accepted by the patients may enable to introduce it regularly in GAD, particularly for people who are resistent to, dependent on or have difficulty in tolerating pharmacology or psychotherapy treatments.

scholarly journals Double-blind clonazepam vs placebo in panic disorder treatment

2000 ◽  
Vol 58 (4) ◽  
pp. 1025-1029 ◽  
Author(s):  
ALEXANDRE MARTINS VALENÇA ◽  
ANTONIO EGIDIO NARDI ◽  
ISABELLA NASCIMENTO ◽  
MARCO A. MEZZASALMA ◽  
FABIANA L. LOPES ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Rating Scale ◽  
Panic Attacks ◽  
Fixed Dose ◽  
Fisher Exact Test ◽  
Double Blind ◽  
Exact Test ◽  
Dsm Iv ◽  
Disorder Treatment ◽  
Hamilton Rating Scale

OBJECTIVE: To assess the effectiveness of clonazepam, in a fixed dose (2 mg/day), compared with placebo in the treatment of panic disorder patients. METHOD: 24 panic disorder patients with agoraphobia were randomly selected. The diagnosis was obtained using the structured clinical interview for DSM-IV . All twenty-four subjects were randomly assigned to either treatment with clonazepam (2 mg/day) or placebo, during 6 weeks. Efficacy assessments included: change from baseline in the number of panic attacks; CGI scores for panic disorder; Hamilton rating scale for anxiety; and panic associated symptoms scale. RESULTS: At the therapeutic endpoint, only one of 9 placebo patients (11.1%) were free of panic attacks, compared with 8 of 13 (61.5%) clonazepam patients (Fisher exact test; p=0,031). CONCLUSION: the results provide evidence for the efficacy of clonazepam in panic disorder patients.

Validation of the Korean version of the Generalized Anxiety Disorder 7 self‐rating Scale

2020 ◽  
Author(s):  
Seung‐Hoon Lee ◽  
Cheolmin Shin ◽  
Hyounwook Kim ◽  
Sang Won Jeon ◽  
Ho‐Kyoung Yoon ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Rating Scale ◽  
Generalized Anxiety ◽  
Self Rating ◽  
Korean Version

Diagnostic efficiency of symptoms in the diagnosis of DSM-IV: generalized anxiety disorder in youth

2002 ◽  
Vol 43 (7) ◽  
pp. 959-967 ◽  
Author(s):  
Armando A. Pina ◽  
Wendy K. Silverman ◽  
Candice A. Alfano ◽  
Lissette M. Saavedra
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Generalized Anxiety ◽  
Diagnostic Efficiency ◽  
Dsm Iv

scholarly journals Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study

2005 ◽  
Vol 20 (3) ◽  
pp. 229-235 ◽  
Author(s):  
Marc Ansseau ◽  
Benjamin Fischler ◽  
Michel Dierick ◽  
Annick Mignon ◽  
Sophie Leyman
Keyword(s):  
Primary Care ◽  
Anxiety Disorder ◽  
Major Depression ◽  
Generalized Anxiety Disorder ◽  
Large Scale ◽  
Screening Program ◽  
Generalized Anxiety ◽  
French Speaking ◽  
Dsm Iv ◽  
Large Scale Screening

AbstractPurposeGADIS aims at determining the prevalence of generalized anxiety disorder (GAD) and major depression (MD) in primary care and their impact on the patient’s functioning in Belgium and Luxemburg.MethodsA large scale screening program was conducted at the consultation of general practitioners to detect patients with GAD and MD according to DSM-IV criteria. We collected additional data regarding the use of hypnotic, tranquilizer, antidepressant and analgesic medications. Impact on the patient was assessed with the Sheehan disability scale.ResultsThree hundred GP’s in Belgium and Luxemburg were asked to screen 50 consecutive patients. Of the 13,677 analyzed patients, 8.3% were diagnosed to have GAD and 6.3% MD. Comorbidity was observed in 4.2% of patients. The prevalence was much higher in the French-speaking part of Belgium. GAD and MD were associated with impairment in social, familial and professional functioning. Only a minority of patients with GAD and/or MD was treated with an antidepressant and almost half of subjects with GAD and/or MD were treated with a tranquilizer.ConclusionsPrevalence rates of GAD and MD in primary care in Belgium are comparable to other countries. GAD and MD are disabling conditions. Antidepressants are still used only in a minority of subjects with GAD and/or MD in primary care in Belgium and Luxemburg. The prevalence of GAD and MD appears to be much higher in French-speaking parts of Belgium.

The 1-Month Prevalence of Generalized Anxiety Disorder According to DSM-IV, DSM-V, and ICD-10 Among Nondemented 75-Year-Olds in Gothenburg, Sweden

2012 ◽  
Vol 20 (11) ◽  
pp. 963-972 ◽  
Author(s):  
Johan Nilsson ◽  
Svante Östling ◽  
Margda Waern ◽  
Björn Karlsson ◽  
Robert Sigström ◽  
...  
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Generalized Anxiety ◽  
Dsm V ◽  
Icd 10 ◽  
Dsm Iv

Generalized anxiety disorder and clinical worry episodes in young women

2002 ◽  
Vol 32 (7) ◽  
pp. 1227-1237 ◽  
Author(s):  
J. HOYER ◽  
E. S. BECKER ◽  
J. MARGRAF
Keyword(s):  
Anxiety Disorder ◽  
Generalized Anxiety Disorder ◽  
Young Women ◽  
Psychosocial Functioning ◽  
Predictive Accuracy ◽  
Community Sample ◽  
Epidemiological Data ◽  
Generalized Anxiety ◽  
Co Morbidity ◽  
Dsm Iv

Background. This article presents epidemiological data on the prevalence of DSM-IV generalized anxiety disorder (GAD) and sub-threshold GAD (fulfilling three out of four GAD criteria) in young women together with data on co-morbidity and psychosocial functioning. The prevalence of clinically relevant worry and its predictive validity for the diagnosis of GAD were also examined.Method. Young women (N = 2064), aged between 18 and 25, from a representative German community sample were diagnosed with a structured clinical interview (ADIS-L, German research version). An additional interview questioned all the participants about the frequency/intensity and uncontrollability of diverse worry topics.Results. Thirty-seven participants (1.8%) fulfilled the criteria of current GAD (1 week point prevalence) and 56 received a lifetime diagnosis (2.7%); a further 50 participants (2.3%) were diagnosed with sub-threshold GAD. Co-morbidity between GAD and other disorders was high for current (68%) and lifetime GAD (91%). GAD, as well as sub-threshold GAD, showed clearly reduced levels of psychosocial functioning. Whereas worries of low intensity and high controllability were ubiquitous in all subsamples, clinically defined worrying was rarely present in healthy subjects (0.89%) and of adequate predictive accuracy for GAD.Conclusions. Full GAD and sub-threshold GAD were moderately frequent in young women. Although DSM-IV worry criteria proved to be highly useful, the strictness of the complete GAD-criteria should not lead to absence of attention from subclinical generalized anxiety states in research and practice.

scholarly journals Association study of the beta-adrenergic receptor genetic variant Gly389Arg and fluoxetine response in major depression

2020 ◽  
Vol 9 ◽  
pp. 1781
Author(s):  
Negar Firouzabadi ◽  
Roja Asadpour ◽  
Kamiar Zomorrodian
Keyword(s):  
Rating Scale ◽  
Response To Treatment ◽  
Adrenergic System ◽  
Major Depressive ◽  
Pcr Rflp ◽  
Dsm Iv ◽  
And Behavior ◽  
Hamilton Rating Scale ◽  
Beta Gene ◽  
Arg389gly Polymorphism

Background: Pharmacogenetics has proven role in the treatment of different illnesses. Patients with special genotypes may achieve a better response to a specific drug. On the other hand, genetic parameters markedly contribute to the development of major depressive disorder (MDD). The significance of adrenergic system compartments in cognition and behavior, and their role in etiology of depression denote that adrenergic receptors beta gene polymorphism(s) might also have an association with drug response. Thus this study aims to evaluate the association between β1AR gene polymorphisms, G1165C, Arg389Gly and response to fluoxetine in MDD patients. Materials and Methods: Among different antidepressants, we focused on fluoxetine as it is prescribed frequently in MDD and belongs to one of the most efficient antidepressant categories with minimum side effects. MDD was diagnosed at study entry using DSM-IV criteria. One hundred and one new MDD patients were treated with fluoxetine for a period of 6 weeks. A 50% decrease in Hamilton Rating Scale for Depression (HRSD) was considered as response to treatment. Genotyping of G1165C polymorphism was performed by PCR-RFLP method. Results: Results of the study indicated no significant relationship between β1AR polymorphism and the patient’s response to fluoxetine neither at genotypic nor allelic level (P=0.568). Conclusion: Our study did not support the hypothesis of involvement of β1AR Arg389Gly polymorphism and response to fluoxetine in MDD patients. [GMJ.2020;9:e1781]

scholarly journals Broadening of Generalized Anxiety Disorders Definition Does not Affect the Response to Psychiatric Care: Findings from the Observational ADAN Study

2012 ◽  
Vol 8 (1) ◽  
pp. 158-168 ◽  
Author(s):  
Enrique Álvarez ◽  
Jose L Carrasco ◽  
José M Olivares ◽  
Vanessa López-Gómez ◽  
Inma Vilardaga ◽  
...  
Keyword(s):  
Psychiatric Care ◽  
Demographic Data ◽  
Anxiety Symptoms ◽  
Generalized Anxiety ◽  
Inclusion Criteria ◽  
Associated Symptoms ◽  
Generalized Anxiety Disorders ◽  
Dsm Iv ◽  
Functional Outcome Measures ◽  
Core Symptoms

Objective:To elucidate the consequences of broadening DSM-IV criteria for generalized anxiety disorder (GAD), we examined prospectively the evolution of GAD symptoms in two groups of patients; one group diagnosed according to DSM-IV criteria and the other, according to broader criteria.Method:Multicentre, prospective and observational study conducted on outpatient psychiatric clinics. Patients were selected from October 2007 to January 2009 and diagnosed with GAD according to DSM-IV criteria (DSM-IV group) or broader criteria. Broader criteria were considered 1-month of excessive or non-excessive worry and only 2 of the associated symptoms listed on DSM-IV for GAD diagnosis. Socio-demographic data, medical history and functional outcome measures were collected three times during a 6-month period.Results:3,549 patients were systematically recruited; 1,815 patients in DSM-IV group (DG) and 1,264 in broad group (BG); 453 patients did not fulfil inclusion criteria and were excluded. Most patients (87.9% in DG, 82.0% in BG) were currently following pharmacological therapies (mainly benzodiazepines) to manage their anxiety symptoms. The changes observed during the study were: 49.0% and 58.0%, respectively of patients without anxiety symptoms as per HAM-A scale at the 6 month visit (p=0.261) and 59.7% and 67.7%, respectively (p=0.103) of responder rates (> 50% reduction of baseline scoring).Conclusion:Broadening of GAD criteria does not seem to affect psychiatric care results in subjects with GAD, is able to identify the core symptoms of the disease according to the DSM-IV criteria and could lead to an earlier diagnosis.

Sign in / Sign up

Export Citation Format

Share Document